Medicinal chemistry, metabolic profiling and drug target discovery: A role for metabolic profiling in reverse pharmacology and chemical genetics

被引：28

作者：

Harrigan, GG ^{[1
]}

Brackett, DJ

Boros, LG

机构：

[1] Pfizer Corp, HTS, Chesterfield, MO 63198 USA

[2] Univ Oklahoma, Hlth Sci Ctr, Dept Surg, Oklahoma City, OK USA

[3] Vet Affairs Med Ctr, Oklahoma City, OK 73104 USA

[4] Univ Calif Los Angeles, Sch Med, Harbor UCLA Res & Educ Inst, Torrance, CA 90509 USA

来源：

MINI-REVIEWS IN MEDICINAL CHEMISTRY | 2005年 / 5卷 / 01期

关键词：

chemical genetics; reverse pharmacology; metabolic profiling; metabolic fingerprinting; metabonomics; metabolomics; SIDMAP;

D O I：

10.2174/1389557053402800

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Comprehensive analysis of the metabolome can contribute to mechanism of action studies for small molecules discovered in phenotypic screens. Examples are presented in this overview of the rapidly developing field of "metabolic profiling." These examples include the use of NMR in gene function analysis, GC-based Studies on the identification of metabolic pathways affected by PPAR-gamma agonists, applications of Fourier-transform MS and the use of stable isotope-based metabolic profiling (SIDMAP) to investigate metabolic adaptive changes induced by effective anticancer agents.

引用

页码：13 / 20

页数：8

共 67 条

[1]

BALLING R, 2001, ANNU REV GENOM HUM G, V2, P363

[2] DISODIUM (R,R)-5-[2-[[2-(3-CHLOROPHENYL)-2-HYDROXYETHYL]AMINO]PROPYL]-1,3-BENZODIOXOLE-2,2-DICARBOXYLATE (CL 316,243) - A POTENT BETA-ADRENERGIC AGONIST VIRTUALLY SPECIFIC FOR BETA-3 RECEPTORS - A PROMISING ANTIDIABETIC AND ANTIOBESITY AGENT [J].